Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Cash & Equivalents data on file, last reported at $8.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 89.9% year-over-year to $8.9 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (down 89.9% YoY), and the FY2025 full-year result was $232.2 million, up 159.76% from the prior year.
• Cash & Equivalents declined to $8.9 million in Q1 2026, from $232.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.5 billion in Q2 2022 to a low of $2.2 million in Q3 2025.
• A 5-year average of $313.9 million and a median of $168.4 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 21390.33% in 2022 and tumbled 98.68% in 2025, its largest moves.
• Tracing VIR's Cash & Equivalents over 5 years: stood at $12.7 million in 2022, then soared by 1805.02% to $241.6 million in 2023, then slumped by 63.0% to $89.4 million in 2024, then surged by 159.76% to $232.2 million in 2025, then plunged by 96.17% to $8.9 million in 2026.
• Business Quant data shows VIR's Cash & Equivalents at $8.9 million in Q1 2026, $232.2 million in Q4 2025, and $2.2 million in Q3 2025.